• Molecular NameMinaprine
  • SynonymMinaprina [INN-Spanish]; Minaprine Dihydrochloride; Minaprine Hydrochloride; Minaprinum [INN-Latin]
  • Weight298.39
  • Drugbank_IDDB00805
  • ACS_NO25905-77-5
  • Show 2D model
  • LogP (experiment)2.03
  • LogP (predicted, AB/LogP v2.0)2.23
  • pkaN/A
  • LogD (pH=7, predicted)2.01
  • Solubility (experiment)2.36 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-1.61
  • LogSw (predicted, AB/LogsW2.0)0.78
  • Sw (mg/ml) (predicted, ACD/Labs)4.09
  • No.of HBond Donors1
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds5
  • TPSA50.28
  • StatusFDA approved; US withdrawn
  • AdministrationN/A
  • PharmacologyAn antidepressant drug which acts as a weak, short-acting monoamine oxidase inhibitor, acting mainly at the MAOA subtype.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic. Cytochrome P4502D is responsible for the 4-hydroxylation of minaprine to 4-hydroxyminaprine.
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)LD50=37 (intraperitoneal)